This study aimed to provide an interim evaluation of the combination of androgen receptor signaling inhibitors denosumab, LRT, and metastasis‐directed therapy (MDT) for prostate cancer with multiple bone metastases (poly‐PCa). This evidence concerns the gene AR and prostate carcinoma.